TP53 and cancer: Expression of murine double minute 2 (Mdm2) can also be targeted by the activation of a ROS-ERK2-MDM2 axis in cancer cells by destabilizing mutant p53 gene, the p53 negative regulator, is commonly amplified and/or overexpressed in numerous cancers, resulting in p53 signaling failure [61].